8-K: AN2 Therapeutics Reports Q1 2025 Financial Results and Highlights Pipeline Progress

AN2 Therapeutics announces its Q1 2025 financial results, reporting a net loss of $10.6 million and a cash runway extending into 2028, while also highlighting advancements in its clinical programs for Chagas disease and melioidosis.

Summary

• AN2 Therapeutics reported its financial results for the first quarter ended March 31, 2025.
• The company had cash, cash equivalents, and investments of $78.5 million as of March 31, 2025.
• AN2 Therapeutics anticipates its cash runway will fund operations into 2028.
• The company is initiating a Phase 1 clinical study of AN2-502998 for Chagas disease, with completion expected in the second half of 2025.
• A Phase 2 study with epetraborole in melioidosis is planned.
• The company intends to use non-dilutive funding to advance epetraborole development for NTM lung disease caused by M. abscessus.
• AN2 Therapeutics is advancing oncology compounds into development later this year.
• First quarter R&D expenses were $7.7 million, compared to $14.7 million for the same period in 2024.
• First quarter G&A expenses were $3.8 million, compared to $3.6 million for the same period in 2024.
• Interest income for the first quarter was $0.9 million, compared to $1.7 million in 2024.
• The net loss for the first quarter of 2025 was $10.6 million, compared to $16.6 million for the same period in 2024.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the extended cash runway, reduced net loss, and progress in clinical programs. However, the company is still operating at a loss and faces risks associated with clinical trials and regulatory approvals.

Positives

• The company's cash runway has been extended to fund operations into 2028.
• The net loss decreased from $16.6 million in Q1 2024 to $10.6 million in Q1 2025.
• The company is advancing its clinical programs for Chagas disease and melioidosis.
• AN2 Therapeutics is leveraging its boron chemistry platform to pursue oncology targets.
• The company is using non-dilutive funding to advance epetraborole development for NTM lung disease.

Negatives

• The company reported a net loss of $10.6 million for the first quarter of 2025.
• Interest income decreased from $1.7 million in Q1 2024 to $0.9 million in Q1 2025 due to lower cash balances and interest rates.
• R&D expenses decreased due to the termination of the EBO-301 clinical study and corporate restructuring activities, which may indicate a change in strategic focus.

Risks

• The company's forward-looking statements are subject to risks and uncertainties, including the ability to implement its plans, enroll patients in clinical trials, and procure sufficient supply of product candidates.
• Clinical trial results may differ from preclinical or early clinical results.
• The company's product candidates may not receive regulatory approvals.
• The company's capital resources may not be sufficient to achieve its goals.
• Global macroeconomic conditions and global conflicts could impact the company's business.

Future Outlook

AN2 Therapeutics anticipates its cash runway will fund operations into 2028 and plans to advance its pipeline, including clinical trials for Chagas disease and melioidosis, and development of oncology compounds.

Management Comments

• Eric Easom, Co-founder, Chairman, President and CEO, stated that the company is poised to advance its pipeline leveraging its boron chemistry platform to address serious unmet needs.
• Eric Easom also mentioned the company remains committed to maintaining a disciplined approach to capital allocation, including using non-dilutive funding to leverage its infrastructure and capabilities for generating near and long-term growth for its shareholders with multiple pathways to success.

Industry Context

AN2 Therapeutics is focused on developing novel small molecule therapeutics derived from its boron chemistry platform, targeting infectious diseases and oncology. The company's programs address unmet needs in Chagas disease, melioidosis, and NTM lung disease, competing with existing treatments and aiming for improved efficacy and oral administration options.

Comparison to Industry Standards

• The company's AN2-502998 for Chagas disease is compared to acoziborole, a related benzoxaborole that demonstrated a ~95% cure rate in a Phase 2/3 trial (DNDi/Sanofi) for human African trypanosomiasis.
• Epetraborole's potential for NTM lung disease is highlighted by its 256-fold in vitro potency advantage over Mycobacterium avium complex (MAC) compared to results from a recent treatment-refractory MAC Phase 3 trial.
• The company estimates peak annual sales potential of $1 billion for its Chagas disease treatment, if approved.

Stakeholder Impact

• Shareholders may benefit from the extended cash runway and potential for pipeline advancements.
• Patients with Chagas disease, melioidosis, and NTM lung disease could benefit from new treatment options.
• Employees are impacted by the corporate restructuring activities and changes in R&D expenses.

Next Steps

• Complete Phase 1 clinical study of AN2-502998 for Chagas disease in the second half of 2025.
• Initiate a Phase 2 study with epetraborole in melioidosis.
• Advance epetraborole development for NTM lung disease using non-dilutive funding.
• Advance the first oncology compound(s) into development later this year.

Key Dates

Keywords

AN2 Therapeutics, Financial Results, Boron Chemistry, Chagas Disease, Melioidosis, NTM Lung Disease, Oncology, Epetraborole, AN2-502998, Clinical Trials